Endocrine therapy is the first line treatment in estrogen receptor (ER) and progesterone receptor (PR) positive breast tumors [3], whereas chemotherapy represents the recommended treatment in patients with the aggressive triple-negative breast cancer (TNBC) [4]. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.